PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), such as monoclonal antibodies targeting programmed cell death protein 1 (PD‐1), programmed cell death protein ligand 1 (PD‐L1), or cytotoxic T cell antigen 4, are utilized as first‐line therapies for a variety of solid and liquid cancers, including NSCLC.